Regulatory Requirements for ML Model Validation

Published on 22/12/2025

How to Validate Machine Learning Models for Clinical Trial Use

Table of Contents

Introduction to ML in Regulated Clinical Environments

As machine learning (ML) models become more integrated into clinical trial operations—ranging from patient recruitment optimization to protocol deviation detection—the need for regulatory-compliant validation becomes paramount. Regulatory authorities including the FDA and EMA expect any system that influences GCP data or decisions to follow a documented validation life cycle, even if it uses AI.

Unlike traditional deterministic software, ML systems are data-driven and often non-deterministic, which adds complexity to their validation. This article explores how regulatory frameworks such as GAMP 5, 21 CFR Part 11, and ICH guidelines apply to ML model validation in the clinical research domain.

Key Regulatory Concepts Applicable to ML Systems

Validation of ML models must align with the core regulatory principles of:

📦 GxP Compliance: The system must demonstrate fitness for intended use and control over inputs/outputs.
📑 Audit Trail: All activities including model training, updates, and outputs must be logged and traceable.
⚙️ Risk-Based Approach: Validation rigor should be proportional to the ML model’s impact on trial outcomes.
📊 Data Integrity: Models must prevent falsification, loss, or manipulation of trial data.
🔧 Documentation: A

comprehensive validation package must be maintained and auditable.

These principles are no different from traditional software validation but must account for AI-specific lifecycle components like training data control and model drift.

Machine Learning Lifecycle and Validation Stages

The lifecycle of an ML model must be clearly defined to structure its validation. A GxP-compliant ML lifecycle includes:

Data Selection and Preprocessing: Documenting dataset origin, curation, transformation, and bias mitigation
Model Development: Recording algorithms, hyperparameters, training iterations, and test data separation
Model Evaluation: Accuracy, precision, recall, F1 score metrics across different datasets
Model Deployment: Defined integration into clinical systems (e.g., eCRF, central monitoring)
Monitoring & Re-Validation: Detecting drift or decreased performance and managing model updates

Tools like model cards and datasheets for datasets, proposed by the AI community, are helpful in documenting model provenance and purpose.

Documented Evidence for Regulatory Submissions

Validation documentation for an ML model must include the following elements:

📝 Intended Use Statement with GxP impact classification
📑 Traceability Matrix: Mapping of functional requirements to testing and validation activities
📄 Design Specification: Model structure, algorithm class, version control
🔒 Access Controls: Who can retrain or modify the model, under what SOP
💻 Test Scripts and Results: Verification of training, validation, and test phases

The PharmaValidation.in site offers downloadable templates tailored to ML validation protocols under GAMP 5 Annexes.

Part 11 and EU Annex 11 Compliance Considerations

To comply with 21 CFR Part 11 and EU Annex 11, ML systems must support:

🔒 Secure User Authentication
📥 Electronic Audit Trails for training and inference activity
📦 Data Retention aligned with study archiving policies
🔧 Electronic Records backed by paper equivalents or metadata

In many cases, ML systems are considered “black box” by regulators. Sponsors should prefer explainable models or use explainability wrappers (e.g., SHAP, LIME) to meet traceability and justification requirements.

Change Control and Revalidation of ML Models

Unlike static software, machine learning models may need periodic retraining. Such changes must undergo proper change control and revalidation to ensure they do not introduce new risks or reduce performance:

📝 Define model versioning and update frequency in SOPs
🛠 Use Change Request forms to document the reason for model retraining
📑 Perform regression testing on old and new models to compare performance
📊 Revalidate with fresh datasets and update training documentation

For example, if a model predicting dropout risk is updated with new site data, it must be evaluated for site bias and algorithmic fairness before redeployment. Regulatory inspectors may expect a side-by-side comparison of model versions during audits.

Vendor Oversight and ML as a Service (MLaaS)

Many organizations rely on third-party ML platforms. Whether models are developed in-house or via vendors, validation responsibilities remain with the sponsor. Critical aspects of vendor oversight include:

📝 Quality Agreements defining validation deliverables and model control
💻 Review of vendor SDLC, training documentation, and infrastructure compliance
⚠️ Access to raw training datasets and documentation of data sources
🔖 SLA (Service Level Agreements) for drift detection and alert mechanisms

Refer to PharmaSOP.in for templates on AI vendor qualification and audit checklists.

Case Study: Validation of a ML System for Adverse Event Classification

A CRO developed an NLP-based machine learning model to classify MedDRA-coded adverse events. The model was trained on historical safety narratives across 12 global studies.

Key Validation Outputs:

📊 Confusion matrix with 92.5% accuracy on unseen AE narratives
📝 Model interpretability using LIME for reviewer acceptance
📦 21 CFR Part 11-compliant audit trail for retraining logs and user inputs
✅ Validation summary report approved by QA and filed in the TMF

This real-world example illustrates that ML validation is achievable within GxP constraints, provided transparency, traceability, and testing are in place.

Emerging Global Regulatory Expectations

While there is no specific FDA or EMA guidance focused exclusively on ML validation yet, draft and reflection papers indicate increasing attention:

These documents reinforce the requirement for validation rigor, explainability, and ongoing performance monitoring, making early adoption of best practices vital for sponsor readiness.

Conclusion

Machine learning has the potential to revolutionize clinical trials, but its adoption must be aligned with regulatory expectations. ML model validation in the pharma sector is not just a technical hurdle—it’s a regulatory imperative. By incorporating lifecycle documentation, explainable models, robust testing, and change control processes, sponsors and CROs can ensure that their AI tools enhance quality without compromising compliance.